Related Experiment Video
Updated: Sep 30, 2026
Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
[Pidotimod in recurring respiratory infection in children with allergic rhinitis, asthma, or both conditions]
Jorge B Vargas Correa1, Sylvia Espinosa Morales, Jorge C Bolaños Ancona
1Servicio de Medicina Interna, Hospital Regional Mérida, ISSSTE, Mérida, Yucatán.
Objective:
To demonstrate a decrease in the number of recurrent breathing infections in patients with allergic rhinitis and asthma, by means of the use of Pidotimod (a immunomodulator).
Material And Methods:
Patients of both sexes, 2 to 16 years old, that had at least four episodes of acute respiratory infection, during the previous six months, administering a dose of 400 mg of pidotimod later, twice a day.
Results:
It was identified a correlation between the number of cases of asthma and those of acute respiratory infection of r = 0.60 with a r2 = 40. A total of 73 patients of both sexes that presented allergic rhinitis and bronchial asthma, had developed at least four acute respiratory infection episodes. Form these patients, 33 were male, a rate that corresponded to 45%, and 40 were female, that corresponded to 55% of population. The average age was 6 years old, with a range from 2 to 16 years. The number of infectious events before using Pidotimod, was 422, with an average of 5.7 for patient, and later to its use, it was 295, that corresponded to 4.04 for each patient, in 6 months. The difference among the means was significant (p < 0.005). The number of days affected by each infectious event was of 446, with an average of 6.10 for patient, and later to administration of the product it was of 308 affected days, that corresponded to an average of 4.21 days for each patient, with a statistical significant of p < 0.001.
Insights
Pidotimod significantly reduced recurrent respiratory infections in children with allergic rhinitis and asthma. This immunomodulator therapy decreased infection frequency and duration, improving patient outcomes.
Area of Science:
- Pediatrics
- Immunology
- Allergology
Context:
- Allergic rhinitis and asthma are common in children, often leading to recurrent respiratory infections.
- These infections can exacerbate underlying conditions and impact quality of life.
- Identifying effective treatments to reduce infection burden is crucial for managing these pediatric conditions.
Purpose:
- To evaluate the efficacy of Pidotimod in decreasing the incidence and severity of recurrent respiratory infections in pediatric patients with allergic rhinitis and asthma.
- To assess the impact of Pidotimod on the number of infectious episodes and associated days of illness.
Summary:
- A study involving 73 children (ages 2-16) with allergic rhinitis and asthma, who experienced at least four respiratory infections in six months, was conducted.
- Patients received Pidotimod (400 mg twice daily).
- Results showed a significant reduction in infectious events from an average of 5.7 to 4.04 per patient and affected days from 6.10 to 4.21 per patient over six months (p < 0.005 and p < 0.001, respectively).
Impact:
- Pidotimod demonstrates significant potential as an immunomodulator to reduce the frequency and duration of respiratory infections in children with allergic rhinitis and asthma.
- This finding suggests Pidotimod as a valuable therapeutic option for managing recurrent infections in this patient population.
- Further research could explore long-term effects and optimal dosing strategies.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:29Respiratory Syncytial Virus Disease
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...